Tirzepatide (Zepbound)
Peptide
Evidence outlook
Approved: Obesity
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Psoriasis · Phase 3Psoriatic Arthritis · Phase 3Crohn's Disease · Phase 3
Also approved (5)
- Moderate to severe obstructive sleep apnea (OSA) in adults with obesity (Zepbound)
- Zepbound: to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity
- Zepbound: obesity disease
- Mounjaro: weight management indication (extension)
- ZEPBOUND (tirzepatide injection) is indicated for once-weekly administration as an adjunct to a reduced-calorie diet and increased physical activity: • for chronic weight management, including weight loss and weight maintenance in adults with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obesity) or • 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight- related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). • to treat moderate to severe obstructive...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SURMOUNT-1 NCT04184622 · Overweight, Obesity SURMOUNT-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 2,539 adults with obesity, or overweight with a weight-related complication, and without diabetes. Participants received weekly tirzepatide 5 mg, 10 mg or 15 mg or placebo for 72 weeks. The co-primary endpoints were the percent change in body weight and the share of participants who lost 5% or more of their weight. In the intention-to-treat analysis, weight fell by 15.0%, 19.5% and 20.9% with the three doses against 3.1% with placebo, and 85% to 91% of tirzepatide participants lost at least 5% against 35% with placebo (P<0.001 for all comparisons), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in the New England Journal of Medicine. Registry: NCT04184622 | 3 | Percent Change From Baseline in Body Weight (Primary Treatment Period) (Baseline, Week 72); Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period) (Week 72) 2022-04-01 | Co-primary 1, percent change in body weight to week 72 (treatment-regimen estimand, ITT): tirzepatide 5 mg -15.0% (95% CI -15.9 to -14.2), 10 mg -19.5% (95% CI -20.4 to -18.5), 15 mg -20.9% (95% CI -21.8 to -19.9) vs placebo -3.1% (95% CI -4.3 to -1.9); P<0.001 for each dose, met. Co-primary 2, weight reduction of 5% or more at week 72: 85%, 89% and 91% vs 35% with placebo; P<0.001 for each dose, met. | Reliable signal | link ↗ |
View 4 more trials
SURMOUNT-2 NCT04657003 · Type 2 Diabetes, Overweight, Obesity This was a randomized, double-blind, placebo-controlled trial in 938 participants using percent change in body weight, the disease-defining endpoint for obesity, as the primary measure. Both the 10 mg and 15 mg tirzepatide doses produced significantly greater weight loss than placebo at 72 weeks. Registry: NCT04657003 | 3 | Percent Change From Baseline in Body Weight (Baseline, Week 72); Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline (Week 72) 2023-03-16 | SURMOUNT-2, n=938. Efficacy estimand % body weight change at Week 72: -13.4% (10mg) and -15.7% (15mg) tirzepatide vs -3.3% placebo. Treatment-regimen estimand: -12.8% (10mg) and -14.7% (15mg) vs -3.2% placebo. Both co-primary objectives (percent body weight change and >=5% weight reduction) met for both estimands. | Reliable signal | link ↗ |
NCT04657016 NCT04657016 · Obesity This was a randomized, double-blind, placebo-controlled trial in 579 people, and both primary endpoints, percent weight change and the share reaching at least 5% further weight loss at 72 weeks, strongly favoured tirzepatide (p<0.001). A power calculation was reported for about 600 participants with more than 90% power; 579 were randomized. Registry: NCT04657016 | 3 | Percent Change From Baseline in Body Weight (Baseline, 72 Weeks); Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction (Week 72) 2023-04-20 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT04660643 NCT04660643 · Obesity After an open-label lead-in, 670 participants were randomly assigned to continue tirzepatide or switch to placebo, with participants and investigators blinded. The primary endpoint, percent change in body weight from randomization to week 88, clearly favoured tirzepatide (p<.001). The protocol's power calculation required 600 randomized participants, and 670 were randomized. Registry: NCT04660643 | 3 | Percent Change From Randomization in Body Weight at Week 88 (Randomization (Week 36), Week 88) 2023-04-25 | Percent Change From Randomization in Body Weight at Week 88 (Randomization (Week 36), Week 88): Tirzepatide MTD -6.7 percent change (Standard Error 0.52) vs Placebo 14.8 percent change (Standard Error 0.53) | Reliable signal | link ↗ |
NCT05412004 NCT05412004 · Obesity Both trials were randomized, double-blind and placebo-controlled, enrolling 469 participants against a planned 412, and in each the primary endpoint, change in AHI at week 52, clearly favoured tirzepatide (p<0.001). Registry: NCT05412004 | 3 | Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52) 2024-03-12 | Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (28)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (30)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (28)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (16)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (2)
What this study did
What this study did
Appears in other studies (4)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other GLP-1/GIP receptor (dual) drugs
Tirzepatide (Mounjaro), BGM0504, Brenipatide, enicepatide, HDM1005 and 7 more. Compare all 13 GLP-1/GIP receptor (dual) drugs
This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Obesity: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tirzepatide (Zepbound): this drug | Approved | Peptide | GLP-1/GIP receptor (dual) | Reliable signal | NCT05412004: Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21) NCT04660643: Percent Change From Randomization in Body Weight at Week 88 (Randomization (Week 36), Week 88): Tirzepatide MTD -6.7 percent change (Standard Error 0.52) vs Placebo 14.8 percent change (Standard Error 0.53) | |
| Liraglutide (Saxenda) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT02918279: Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54) NCT01557166: Change From Baseline in Apnoea-hypopnoea Index (AHI) (Week 0, Week 32): Liraglutide 3.0 mg -12.22 events/hour (Standard Deviation 23.34) vs Placebo -6.08 events/hour (Standard Deviation 25.9) | |
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination), Dopamine/norepinephrine transporter | not yet graded | NCT03374956: Change in Total Body Weight (baseline to 12 weeks): Intervention Group -7.7% (IQR -11 to -4.7) vs Control Group -6.5% (IQR -11 to -2.3) phase 3 result · pivotal pending | |
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | Partial signal | NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met. | |
| Orlistat (Xenical) | Approved | Small molecule | Pancreatic/gastric lipase | Weak signal | No reviewed efficacy summary in this indication | |
| Phentermine / Topiramate (Qsymia) | Approved | Small molecule | Noradrenergic/anticonvulsant (combination) | Reliable signal | NCT00553787: Percent Weight Loss From Baseline to Week 56 (Baseline to 56 weeks): VI-0521 Mid 7.81% (Standard Error 0.365) | VI-0521 Top 9.84% (Standard Error 0.275) vs Placebo 1.24% (Standard Error 0.277) NCT00554216: Percent Weight Loss From Baseline to Week 56 (baseline to 56 weeks): VI-0521 Low 5.1% (Standard Error 0.538) | VI-0521 Top 10.92% (Standard Error 0.392) vs Placebo 1.55% (Standard Error 0.395) | |
| Semaglutide (Wegovy Tablets) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Semaglutide (Wegovy) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 NCT03548935: Change in Body Weight (%) (Baseline (week 0) to week 68): Semaglutide 2.4 mg — In-trial observation period: -15.6% (Standard Deviation 10.1); On-treatment observation period: -16.9% (Standard Deviation 9.4) vs Placebo — In-trial observation period: -2.8% (Standard Deviation 6.5); On-treatment observation period: -3.1% (Standard Deviation 6.4) | |
| Setmelanotide (Imcivree) | Approved | Peptide | MC4R | Weak signal | NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984) NCT03287960: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52): Setmelanotide (Entire Study) 45.5% (95% CI 19.96 to 72.88) | |
| Tirzepatide (Mounjaro) | Approved(overall) | Peptide | GLP-1/GIP receptor (dual) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | NCT06703021: Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) | |
| ASC30 | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | NCT07002905: Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo | |
| Berobenatide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | NCT06712836: Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). | |
| BGM0504 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | Partial signal | NCT06973681: Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity) | |
| Bofanglutide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Cagrilintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | Reliable signal | NCT03856047: Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2) | |
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual) | Reliable signal | NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) NCT05813925: Change in body weight at week 68: -18.4% (SE 0.7) CagriSema vs -11.9% (SE 0.7) semaglutide alone; ETD -6.5 percentage points (95% CI -8.4 to -4.6; p<0.0001) | |
| DA-302168S | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | Reliable signal | NCT05813795: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met. | |
| Efmedaglutide Alfa (Shanmeining) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | Partial signal | NCT05997576: Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025). | |
| Efpeglenatide | Phase 3 | Peptide | GLP-1 receptor | Reliable signal | NCT06174779: Percent change in body weight from baseline at Week 40: -9.75% (efpeglenatide/HM11260C) vs -0.95% (placebo); least-squares mean difference -8.13 percentage points, statistically significant | |
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Eloralintide | Phase 3 | Peptide | Amylin receptor | Reliable signal | NCT06230523: Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%. | |
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | Reliable signal | NCT06525935: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) | |
| HDM1002 | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| HDM1005 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Lenbelintide | Phase 3 | Peptide | Amylin receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Maridebart Cafraglutide (MariTide) | Phase 3 | Peptide | GLP-1R agonist; GIPR antagonist | Reliable signal | NCT05669599: Primary endpoint percent change in body weight baseline to week 52 (treatment policy estimand): -12.3% to -16.2% across doses vs -2.5% placebo (obesity cohort); -8.4% to -12.3% vs -1.7% placebo (obesity-diabetes cohort) | |
| Mazdutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Reliable signal | NCT05607680: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met. | |
| MDR-001 | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Mibavademab | Phase 3 | Monoclonal antibody | Leptin receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Olatorepatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | Reliable signal | NCT06839664: Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. | |
| Petrelintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | Partial signal | NCT06662539: Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). | |
| RAY1225 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Retatrutide | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | Partial signal | NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. NCT05931367: Co-primary 1, WOMAC pain subscale change to week 68 (treatment-regimen estimand): retatrutide 9 mg -4.0 points (-67.2%), 12 mg -3.7 points (-62.6%) vs placebo -2.1 points (-35.1%); statistically significant for each dose per the sponsor (p not printed), met. Co-primary 2, percent change in body weight to week 68: 9 mg -20.0%, 12 mg -23.7% vs placebo -4.6%; statistically significant for each dose per the sponsor (p not printed), met. | |
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | Reliable signal | NCT06396429: Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss | |
| Safiglipron (HRS-7535) | Phase 3 | Small molecule | GLP-1 receptor | Reliable signal | NCT06904105: Percent body-weight change at week 44, treatment-policy estimand (prespecified primary): -8.0% (120 mg) and -9.8% (180 mg) vs -2.4% placebo, superiority stated as met (no p-value given). Proportion with at least 5% weight loss at week 44 (registry primary): 58.6% (120 mg) and 68.2% (180 mg); placebo rate and significance not reported. | |
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | NCT06066515: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo). NCT06066528: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo). | |
| Tesofensine | Phase 3 | Small molecule | Noradrenaline/dopamine/serotonin reuptake | Reliable signal | NCT00394667: After 24 weeks, mean weight loss with diet and placebo was 2.0%, while tesofensine doses produced significantly greater reductions of 4.5%, 9.2% and 10.6% respectively. | |
| UBT251 | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| VCT220 | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | NCT06939296: Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18). NCT07011797: Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding. | |
| VK2735 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | Reliable signal | NCT06828055: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 | |
| Zenagamtide | Phase 3 | Peptide | GLP-1/amylin receptor (dual) | Weak signal | NCT06064006: Primary outcome, safety (number of treatment-emergent adverse events; no formal efficacy test). Secondary endpoint, estimated mean bodyweight change vs placebo: -24.3% vs -1.1% at week 36 (60 mg), -22.0% vs 1.9% (20 mg, week 36), -16.2% vs 2.3% (5 mg, week 28), -9.7% vs 2.0% (1.25 mg, week 20); p<0.0001 (Parts A-D), p=0.0003 (Part E) (Lancet 2025). | |
| Zovaglutide | Phase 3 | Peptide | GLP-1 receptor | Reliable signal | NCT07020884: Percentage change in body weight from baseline at 24 weeks: -10.6% (80mg monthly), -13.8% (160mg monthly), -12.5% (80mg biweekly), -14.4% (160mg biweekly) vs -2.4% (placebo); p<0.0001. | |
| Efsubaglutide Alfa | Phase 2/3 | Protein / enzyme therapeutic | GLP-1 receptor | Partial signal | NCT06732960: Efsubaglutide Alfa produced a mean weight reduction of 7.16% (95% CI: -8.08 to -6.24) versus 0.86% with placebo. Overall, 82.5% of Efsubaglutide-treated participants achieved >=5% weight loss (vs. 0% placebo). | |
| ABBV-295 | Phase 2 | Peptide | Amylin receptor | Weak signal | Featured results are safety only in this race | |
| Apitegromab (Isembyld) | Phase 2 | Monoclonal antibody | Myostatin (pro/latent form) | Partial signal | NCT06445075: Change from baseline in total Lean Body Mass at 24 weeks: -1.6 kg (-3.4 lbs) with apitegromab+tirzepatide vs -3.5 kg (-7.6 lbs) with placebo+tirzepatide; difference 1.9 kg (4.2 lbs) less lean-mass loss with apitegromab, i.e. 54.9% relative preservation (p=0.001). | |
| ARD-101 | Phase 2 | Small molecule | Bitter taste receptor (gut) | Partial signal | NCT05121441: General-obesity Phase 2 (n=20): ARD-101 produced a 2.51-fold greater reduction in hunger rating (Control of Eating Questionnaire) vs placebo; p=0.015 | |
| AT-7687 | Phase 2 | Peptide | GIPR antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| AZD9550 | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | No reviewed efficacy summary in this indication | |
| BGM1812 | Phase 2 | Peptide | Amylin/calcitonin receptor (dual) | Weak signal | NCT07224399: Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026) | |
| BI 3034701 | Phase 2 | Peptide | GLP-1/GIP/NPY2 receptor (triple) | Weak signal | No reviewed efficacy summary in this indication | |
| Bimagrumab | Phase 2 | Monoclonal antibody | Activin/myostatin type II receptor | Partial signal | NCT05616013: Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): 30 mg/kg Bimagrumab -9.25 kilogram (kg) (Standard Error 1.33) | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide -12.73 kilogram (kg) (Standard Error 1.29) | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide -14.31 kilogram (kg) (Standard Error 1.34) | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide -13.86 kilogram (kg) (Standard Error 1.29) | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide -17.79 kilogram (kg) (Standard Error 1.29) vs Placebo + 1.0 mg Semaglutide -9.76 kilogram (kg) (Standard Error 1.25) | Placebo + 2.4 mg Semaglutide -14.24 kilogram (kg) (Standard Error 1.17) | |
| Bremelanotide (Vyleesi) | Phase 2 | Peptide | MC4R | Reliable signal | NCT06565611: BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001. | |
| Dapiglutide | Phase 2 | Peptide | GLP-1/GLP-2 receptor (dual) | Partial signal | NCT05788601: NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. missed | |
| ECC4703 | Phase 2 | — | Thyroid hormone receptor beta (THRβ) | not yet graded | No reviewed efficacy summary in this indication | |
| Ecnoglutide (VRB-101) | Phase 2 | Peptide | GLP-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Enobosarm | Phase 2 | Small molecule | Androgen receptor (selective) | Partial signal | NCT06282458: Change in total lean body mass at 16 weeks (day 112), enobosarm+semaglutide vs placebo+semaglutide: 71% relative reduction in lean mass loss (p=0.002); 27% greater fat loss vs control | |
| ERX1000 | Phase 2 | Small molecule | Leptin | Weak signal | No reviewed efficacy summary in this indication | |
| Garetosmab (Pasatru) | Phase 2 | Monoclonal antibody | Activin A | not yet graded | No reviewed efficacy summary in this indication | |
| HM15275 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | Weak signal | Featured results are safety only in this race | |
| HRS-4729 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | Weak signal | Featured results are safety only in this race | |
| LAE102 | Phase 2 | Monoclonal antibody | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary in this indication | |
| Macupatide | Phase 2 | Peptide | GIP receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Metreleptin (Myalept) | Phase 2 | Protein / enzyme therapeutic | Leptin | Partial signal | No reviewed efficacy summary in this indication | |
| NA-931 | Phase 2 | Peptide | GLP-1/GIP/glucagon/IGF-1 receptors (quadruple) | Partial signal | NCT06564753: Mean body weight reduction from baseline at Week 13: up to 13.8% at the 150 mg daily dose; 11.9% relative to placebo | |
| Nimacimab | Phase 2 | Monoclonal antibody | CB1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| NNC0519-0130 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | Partial signal | No reviewed efficacy summary in this indication | |
| NNC0662-0419 | Phase 2 | Peptide | GLP-1 / GIP / Amylin receptors | Weak signal | No reviewed efficacy summary in this indication | |
| Orlistat / Acarbose (EMP16) | Phase 2 | Small molecule | GI lipase + intestinal alpha-glucosidase | Partial signal | No reviewed efficacy summary in this indication | |
| THDBH120 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | Weak signal | Featured results are safety only in this race | |
| Brenipatide | Phase 1 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| KP405 | Phase 1(overall) | Peptide | GLP-1/GIP receptor (dual) | Partial signal(overall) | No reviewed efficacy summary in this indication |
Large race: only the 72 furthest-along competitors are listed; 48 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(80 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tirzepatide (Zepbound) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (10)
November 2026 (4)
What to watch
What to watch
What to watch
What to watch
2027 (36)
January 2027 (1)
What to watch
February 2027 (3)
What to watch
March 2027 (2)
April 2027 (4)
May 2027 (2)
June 2027 (3)
What to watch
What to watch
What to watch
July 2027 (3)
What to watch
What to watch
What to watch
August 2027 (3)
September 2027 (5)
What to watch
October 2027 (4)
What to watch
What to watch
What to watch
November 2027 (1)
December 2027 (5)
What to watch
What to watch
What to watch
2028 (18)
January 2028 (2)
February 2028 (3)
April 2028 (1)
May 2028 (3)
What to watch
June 2028 (1)
July 2028 (1)
August 2028 (1)
What to watch
September 2028 (2)
December 2028 (4)
What to watch
What to watch
What to watch
2029 (14)
March 2029 (1)
What to watch
April 2029 (1)
May 2029 (1)
What to watch
June 2029 (1)
July 2029 (1)
August 2029 (3)
September 2029 (1)
What to watch
October 2029 (3)
2030 (1)
February 2030 (1)
What to watch
2034 (1)
December 2034 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent